Bedrijfsoverzicht
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the development and commercialization of cancer therapies within the United States market. The company operates within the Healthcare sector, specifically the Biotechnology industry, which implies a focus on high-risk, high-reward research and development phases aimed at bringing novel treatments to patients. The entity employs a workforce of 601 individuals and holds a total market capitalization of $2.80B, while reporting trailing twelve-month revenue of $247.00M. These financial dimensions suggest that the company has secured significant market valuation despite not yet generating net profits, indicating that investors are pricing in the potential future success of its development pipeline rather than current operational earnings. The substantial market cap relative to its current revenue stream highlights the market's expectation of substantial future scalability and the commercial success of its asset portfolio, including its HIF-2a inhibitor and anti-TIGIT antibody candidates.
Financiële gezondheid
The company reported annual revenue of $247.00M over the trailing twelve months, yet this generated a net income of $-353,000,000 and an EBITDA of $-376,000,000. The significant disparity between positive revenue and substantial net losses reveals a cost structure heavily weighted toward research and development expenses typical of a clinical-stage biotechnology firm where revenue does not yet cover operating costs. Free cash flow stands at $-162,250,000, indicating that the company is currently burning cash to fund its operations and drug development programs, which limits immediate financial flexibility but is often necessary for growth in this sector. The gross margin is recorded at -111.7%, the operating margin at -345.5%, and the profit margin at -142.9%, all of which reflect the intense upfront capital requirements before a company achieves profitability in the biotechnology industry. On the balance sheet, the company holds $981.00M in cash against $219.00M in debt, supported by a debt-to-equity ratio of 34.71, suggesting a relatively conservative leverage position given the depth of available liquidity. The current ratio of 4.36 demonstrates strong short-term liquidity, indicating that the company possesses more than four times the current assets necessary to cover its short-term liabilities. Return on Equity is -63.3% and Return on Assets is -21.1%, metrics that reveal that management is currently deploying capital to generate losses rather than returns, a common characteristic of companies in the development phase.
Waarderingsbeoordeling
The valuation metrics present a challenging picture for traditional investors, with a P/E Ratio (TTM) listed as N/A due to negative earnings, while the Forward P/E is calculated at -6.40. The existence of a negative forward P/E implies that the market expects earnings to remain negative in the near future, preventing a standard earnings-based valuation from being applied. The price-to-book ratio stands at 4.44, indicating that the market is pricing the company at a significant premium over its book value, likely reflecting the intangible value of its intellectual property and clinical pipeline. Alternative valuation metrics such as the price-to-sales ratio of 11.34 and an EV/EBITDA of -5.42 suggest that investors are valuing the company primarily on its revenue generation potential and asset base rather than profitability. The stock has traded between a 52-week low of $7.06 and a 52-week high of $26.40, and the current trading level sits dynamically within this volatility range, subject to market sentiment regarding its clinical progress. The beta value of 0.86 indicates that the stock's price volatility is slightly lower than the broader market, suggesting a margin of stability relative to the high-beta biotechnology sector despite its inherent risks.
Growth & Income
Revenue growth year-over-year is recorded at 26.9%, while earnings growth is listed as N/A due to the company's current unprofitability. The disparity between positive revenue growth and the inability to calculate earnings growth implies that top-line expansion is outpacing the ability to convert those sales into net income, a standard trajectory for companies scaling up from clinical trials. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available resources and capital into research and development rather than distributing income to shareholders. This reinvestment strategy prioritizes the advancement of its therapeutic candidates over immediate shareholder returns, which is a deliberate financial policy common in biotechnology firms seeking to capture future market share. The overall growth and income profile is characterized by rapid revenue expansion paired with significant cash consumption, offering potential future upside contingent on the successful commercialization of its pipeline while providing no current income stream for investors.